Research Reports Coverage on Healthcare Stocks -- Antares Pharma, Insulet, Glaukos, and CR Bard
NEW YORK, October 13, 2016 /PRNewswire/ --
The U.S. Medical Instruments and Supplies segment is mature and consolidating with relatively high profit margins. Companies in this space research, develop, and produce non-electronic medical, surgical, dental, and veterinary instruments and apparatus, and offer below-average dividend yields when compared to the wider market. This morning, Stock-Callers.com highlights four equities for assessment: Antares Pharma Inc. (NASDAQ: ATRS), Insulet Corp. (NASDAQ: PODD), Glaukos Corp. (NYSE: GKOS), and CR Bard Inc. (NYSE: BCR). These stocks research reports can be downloaded now by simply registering for free at: http://stock-callers.com/registration
Antares Pharma
On Wednesday, shares in Ewing, New Jersey headquartered Antares Pharma Inc. recorded a trading volume of 404,965 shares. The stock ended the day at $1.72, dropping 3.37%. The Company's shares have surged 32.31% in the last one month, 72.00% over the previous three months, and 42.15% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 24.19% and 58.84%, respectively. Furthermore, shares of Antares Pharma, which focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide, have a Relative Strength Index (RSI) of 60.36.
On September 22nd, 2016, Antares Pharma announced safety results from the dose-blinded, multiple-dose, concentration-controlled, 26-week phase 3 study of QuickShot® Testosterone (QST) administered subcutaneously once each week to adult males with hypogonadism. The study, QST-15-005, included a screening phase, a titration phase and a treatment phase for evaluation of safety and tolerability, including laboratory assessments, adverse events and injection site assessments. The safety population, defined as patients who received at least one dose of study drug, was comprised of 133 patients. The most common adverse reactions (incidence ≥5%) in this study were increased hematocrit, upper respiratory tract infection and injection site ecchymosis. Your complete research report on ATRS can be retrieved for free at: http://stock-callers.com/registration/?symbol=ATRS
Insulet
Billerica, Massachusetts headquartered Insulet Corp.'s stock finished yesterday's session 0.26% higher at $38.89 and with a total trading volume of 286,108 shares. The Company's shares have gained 18.39% over the previous three months and 2.86% on an YTD basis. The stock is trading above its 200-day moving average by 13.21%. Furthermore, shares of Insulet, which develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the US, have an RSI of 37.26.
As per notes filed with the SEC on September 13th, 2016, Insulet closed its previously announced issuance and sale of $345 million aggregate principal amount of the company's 1.25% Convertible Senior Notes due 2021 pursuant to the terms of a purchase agreement, dated September 7th, 2016, by and between the company and Morgan Stanley & Co. LLC and Wells Fargo Securities, as the representatives of the initial purchasers. PODD free report is just a click away at: http://stock-callers.com/registration/?symbol=PODD
Glaukos
At the closing bell on Wednesday, shares in Laguna Hills, California headquartered Glaukos Corp. saw a drop of 1.05%, ending the day at $35.78. The stock recorded a trading volume of 560,899 shares, which was above its three months average volume of 534,350 shares. The Company's shares have advanced 4.80% in the last one month, 15.98% in the previous three months, and 44.92% since the start of this year. The stock is trading 4.42% above its 50-day moving average and 42.45% above its 200-day moving average. Moreover, shares of Glaukos, which develops and commercializes products and procedures designed for the treatment of glaucoma, have an RSI of 43.72.
On September 27th, 2016, Glaukos announced that a study published in Clinical Ophthalmology showed that a consistent cohort of 107 open-angle glaucoma eyes receiving the iStent® Trabecular Micro-Bypass Stent in combination with cataract surgery achieved a 22% reduction in mean intraocular pressure (IOP) to 15.17 mm Hg and a 56% reduction in mean ocular hypotension medications to 0.61 two years following surgery. Sign up for your complimentary research report on GKOS at: http://stock-callers.com/registration/?symbol=GKOS
CR Bard
Murray Hill, New Jersey headquartered CR Bard Inc.'s stock ended the day 0.03% higher at $217.82. A total volume of 536,144 shares was traded, which was above their three months average volume of 463,060 shares. The Company's shares have gained 2.25% in the last month and 15.40% on an YTD basis. The stock is trading 3.52% above its 200-day moving average. Additionally, shares of CR Bard, which together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide, have an RSI of 40.64.
On September 16th, 2016, research firm Wells Fargo upgraded the Company's stock rating from 'Market Perform' to 'Outperform'.
On October 12th, 2016, C. R. Bard's Board of Directors declared a regular quarterly dividend of $0.26 per share on Bard's common stock. The dividend is payable on November 4th, 2016 to shareholders of record at the close of business on October 24th, 2016. Register for free on Stock-Callers.com and download the latest research report on BCR at: http://stock-callers.com/registration/?symbol=BCR
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Share this article